RxDoctor Payments DataLook up a doctor →

Ahmad Sabouni, MD

Neurology · Lubbock, TXNPI 1124199187

Payments from drug & device makers

$737,310in general payments, 2019–2025

Across 1,545 payments — averaging $477.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$585K
  • TG Therapeutics, Inc.$87K
  • AbbVie$36K
  • Biogen$11K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Neurocrine Biosciences, Inc.$1K
  • plus $15K from 54 others

What the payments were for

  • Consulting fees$5761%
  • Speaking & faculty fees$41,63163%
  • Food & beverage$23,70536%
  • Education$5871%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis60$584,778
TG Therapeutics, Inc.33$87,442
AbbVie(2 entities)229$35,569
Biogen80$10,857
Teva Pharmaceuticals USA, Inc.152$1,755
Neurocrine Biosciences, Inc.101$1,347
Supernus Pharmaceuticals, Inc.98$1,145
EMD Serono, Inc.83$1,104
Amgen(2 entities)56$1,044
UCB, Inc.51$840
Lundbeck LLC39$748
AstraZeneca24$692
Lilly USA, LLC39$675
Abbott33$538
SK Life Science, Inc.28$504
Pfizer34$486
Argenx US, Inc.22$474
Acadia Pharmaceuticals Inc27$444
Merz Pharmaceuticals, LLC20$443
Sanofi19$426
Amneal Pharmaceuticals LLC24$380
Biohaven Pharmaceutical Holding Company Ltd.25$365
Genentech USA, Inc.20$336
Medtronic(2 entities)20$335
Acorda Therapeutics, Inc15$310
Kyowa Kirin, Inc.16$304
Revance Therapeutics, Inc.6$302
Eisai Inc.11$289
Harmony Biosciences LLC12$248
MDD US Operations, LLC17$239
Sunovion Pharmaceuticals Inc.21$229
Upsher-smith Laboratories LLC9$200
GRT US Holding, Inc.4$198
Amylyx Pharmaceuticals, Inc.11$191
Adamas Pharmaceuticals, Inc.9$165
Bristol Myers Squibb9$160
Takeda Pharmaceuticals U.S.A., Inc.5$131
CSL Behring5$127
Averitas Pharma Inc.5$121
Tanabe Pharma America, Inc.7$118
Ipsen Biopharmaceuticals, Inc6$110
Avanir Pharmaceuticals, Inc.7$93
Otsuka America Pharmaceutical, Inc.4$90
Vanda Pharmaceuticals Inc.4$73
Jazz Pharmaceuticals Inc.4$71
Greenwich Biosciences, Inc.4$70
GE HealthCare6$68
EDW Pharma, Inc.1$65
Akcea Therapeutics, Inc.1$64
Biohaven Pharmaceuticals, Inc.4$63
E.r. Squibb & Sons, L.L.C.3$58
NS Pharma, Inc.2$45
Neurelis, Inc.2$36
Boston Scientific1$36
Alnylam Pharmaceuticals Inc.2$32
Mallinckrodt Enterprises LLC1$32
Grifols USA, LLC2$28
Merz North America, Inc.1$27
Johnson & Johnson1$26
Assertio Therapeutics, Inc.2$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$737,310 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$3,912,619
Medicare patients
1,423
Services billed
224,913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine56$418,362
IngrezzaValbenazine Tosylate42$380,277
NuplazidPimavanserin Tartrate27$137,978
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5024$106,484
TecfideraDimethyl Fumarate12$105,014
Avonex Pen (4 Pack)Interferon Beta-1a12$99,190
BotoxOnabotulinumtoxina55$88,353
GocovriAmantadine Hcl21$84,805
XcopriCenobamate55$81,310
Dimethyl Fumarate28$80,296
PanzygaImmun Glob G(Igg)-Ifas/Glycine19$73,936
Austedo XrDeutetrabenazine11$72,039
HizentraImmun Glob G(Igg)/Pro/Iga 0-5011$64,849
QuliptaAtogepant34$58,279
Nurtec OdtRimegepant Sulfate30$48,141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$1,755$490,40167 claims
Neurocrine Biosciences, Inc.Ingrezza$1,347$380,27742 claims
AbbVieBotox, Qulipta$35,569$146,63289 claims
Acadia Pharmaceuticals IncNuplazid$444$137,97827 claims
PfizerPanzyga, Nurtec Odt$486$122,07749 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$131$106,48424 claims
BiogenTecfidera$10,857$105,01412 claims
MDD US Operations, LLCGocovri$239$84,80521 claims
SK Life Science, Inc.Xcopri$504$81,31055 claims
CSL BehringHizentra$127$64,84911 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$380$52,273196 claims
Grifols USA, LLCGamunex-C$28$44,97423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 neurology providers in Texas.

Other neurology in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →